Moderna Faces Analyst Downgrades Amid Profitability and Growth Concerns

Moderna (NASDAQ: MRNA) shares are facing headwinds in premarket trading, signaling that the company may be in for a rough ride as analysts cut their ratings amidst concerns over future profitability.

Following a sharp decline in its stock price the day before, which brought it alarmingly close to a four-year low, the outlook for the biotech firm appears murkier than ever.

The root of the recent turmoil stems from Moderna's announcement that it now anticipates reaching a break-even point in operating cash of $6 billion by 2028—two years later than previously projected. Expectations for revenue in 2025 have also been revised downwards, with the company forecasting figures between $2.5 billion and $3.5 billion, falling short of the Wall Street consensus of $3.74 billion, as reported by LSEG. To add salt to the wound, this midpoint revenue forecast is lower than its earlier sales estimates of $3 billion to $3.5 billion for 2024.

Analysts at Jefferies downgrading their recommendation for Moderna from "Buy" to "Hold," highlighting concerns that the company may need to seek additional capital to meet these revised expectations. Such a move could become necessary as the company grapples with diminishing demand for its COVID-19 vaccines in a post-pandemic landscape.

Furthermore, Moderna acknowledged delays in receiving regulatory approvals for its flu and cancer vaccines, pushing back its timeline significantly. In a bid to offset its financial burdens, the company plans to slash its research and development expenditures by roughly $1.1 billion starting in 2026, reducing its projected costs from $4.8 billion this year down to a range of $3.6 billion to $3.8 billion by 2027.

Analysts at JPMorgan Chase (NYSE: JPM) have lowered their rating to "Underweight" from "Neutral," suggesting that the stock might struggle to keep pace with its competitors in the industry.

In an interview, Chief Financial Officer James Mock clarified that the revenue from the ten new products anticipated to gain regulatory approval by 2027 would only start to flow after the green light from authorities.